FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC

Daiichi Sankyo and partner AstraZeneca said on October 17 that the US FDA has granted a priority review status for their hoped-to-be-blockbuster breast cancer drug trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC), with the agency’s decision expected by mid-next...read more